Figure 1.

Assessment of the variation in reported half‐maximal effective concentration (EC₅₀) values for severe acute respiratory syndrome‐coronavirus 2 across the drugs for which more than one value was available in the literature (a). The consequences of this variability in reported EC₅₀ in terms of the peak plasma concentration (C_max)/EC₅₀ ratio is also provided (b). Amodiaquine and toremifene were estimated to exhibit subtherapeutic pharmacokinetics irrespective of which EC₅₀ value was used. Similarly, nelfinavir was estimated to have C_max value higher than its EC₅₀ irrespective of which EC₅₀ was used in the analysis. For the other drugs, interpretation was highly dependent upon which reported EC₅₀ was utilised and this underscores the caution that should be taken in interpreting the available data.